Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity treatments improve.

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration

Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ) that's also probably bad news for Hims & Hers Health ( HIMS -17.80%).

In a statement, the FDA said it confirmed Novo Nordisk's "stated product availability and manufacturing capacity" of these prescription drugs meets or exceeds current and projected demand.

Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others believe these drugs are dangerous for patients.

Compounders have filed a lawsuit against the FDA challenging its decision to remove Novo Nordisk's Wegovy and Ozempic from the shortage list. The lawsuit claims the FDA's actions are arbitrary, impacting the sale of cheaper compounded versions.